Markets & Regulations

© Getty Images

Finch halts biotherapeutic trial and axes 95 per cent of its staff

By Liza Laws

Finch Therapeutics announced its shock decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) yesterday (Jan 25) saying instead it will focus on ‘realizing the value of its intellectual property estate and...

© GettyImages/Ca-ssis

Lonza: Robust industry fundamentals are supportive of growth

By Jane Byrne

Despite an uncertain macroeconomic environment, Lonza says its ‘resilient’ business model and sustained market demand delivered a strong financial performance in 2022, in line with the Swizterland based CDMO’s outlook.

© GettyImages/Andrew Brookes

Needle-free future: Tackling vaccine delivery challenges

By Jane Byrne

Biotech company, Vaxxas, has secured a partnership agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its needle-free vaccine-patch delivery technology for mRNA vaccines.

© GettyImages/ArtemisDiana

Lumen Bio: ‘We face 2023 with tremendous optimism’

By Jane Byrne

Lumen Bioscience has been highlighting recent progress made on its clinical and regulatory journey while also announcing several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases.

© GettyImages/AlexanderFord

Opus acquires two compounds for inherited retinal diseases

By Jane Byrne

Last week saw Opus Genetics announce it had acquired the rights to two preclinical-stage adeno-associated virus (AAV)-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio.

Follow us

Webinars